Get the Stockscreener App
2.73
1.49%
0.04
Serina Therapeutics Inc stock is traded at $2.73, with a volume of 14,840.
It is up +1.49% in the last 24 hours and up +27.57% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$2.69
Open:
$2.7
24h Volume:
14,840
Relative Volume:
0.18
Market Cap:
$69.34M
Revenue:
$130.00K
Net Income/Loss:
$-21.29M
P/E Ratio:
-1.3809
EPS:
-1.977
Net Cash Flow:
$-18.29M
1W Performance:
+10.98%
1M Performance:
+27.57%
6M Performance:
+63.47%
1Y Performance:
-48.30%
1-Day Range:
$2.5121
$2.74
1-Week Range:
$2.38
$2.74
52-Week Range:
$1.22
$5.83
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.73 | 67.31M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
BTIG Maintains Serina Therapeutics(SER.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Serina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero - scanx.trade
Serina Therapeutics Completes Dosing for 8 Parkinson’s Patients - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SER Q1 2026 Earnings: Wider Loss Falls Short of Estimates Despite Modest Share GainEarnings Trend Analysis - vinanet.vn
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics (SER) Holds Steady Above $2.24 Support, Up 0.43% in Measured SessionVolatility Smile - dars.gov.et
Serina Therapeutics (SER) Advances 5.83% to $2.18, Approaching Key Resistance at $2.29Wave Truncation - vinanet.vn
SER Q1 2026 Earnings: Wider-than-Expected Loss of -$0.58 per Share Signals Rising Pipeline CostsEarnings Call Highlights - Vinanet
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Serina Therapeutics (SER) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseEstimate Dispersion - dars.gov.et
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewswire
Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Nigeria
Juvenescence group reports 27.3% Serina Therapeutics (SER) beneficial stake - Stock Titan
Serina Therapeutics (SER) Gains Ground: Testing Resistance at $2.28VWAP Breakout - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises 7.58%Financial Data - dars.gov.et
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Miss Exceeds 30% as Clinical-Stage Firm Ramps R&D SpendEPS Growth Report - Vinanet
SER Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Pipeline AdvancesEarnings Growth Forecast - po-news-eg.net
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Call Transcript - vinanet.vn
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Taiwan News
Serina Therapeutics director Brannan buys $2,029 in stock - Investing.com UK
Insider Buying: Stephen Brannan Acquires Shares of Serina Therap - GuruFocus
Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Serina Therapeutics Inc Stock (SER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venkatesan Jay | Director |
May 22 '26 |
Buy |
1.78 |
589 |
1,048 |
589 |
| WILSON KAREN J | Director |
Jun 11 '26 |
Buy |
1.75 |
5,100 |
8,900 |
5,100 |
| WILSON KAREN J | Director |
Jun 12 '26 |
Buy |
1.77 |
5,000 |
8,850 |
10,100 |
| WILSON KAREN J | Director |
May 22 '26 |
Buy |
1.93 |
10,000 |
19,300 |
20,000 |
| WILSON KAREN J | Director |
May 21 '26 |
Buy |
1.77 |
10,000 |
17,700 |
10,000 |
| Marshall Richard Peter | Director |
May 19 '26 |
Buy |
1.65 |
12,183 |
20,102 |
12,183 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Option Exercise |
0.06 |
6,500 |
390 |
6,500 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Sale |
2.86 |
6,500 |
18,568 |
0 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Option Exercise |
0.06 |
39,000 |
2,340 |
39,000 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Sale |
2.50 |
39,000 |
97,500 |
0 |
0.86%
0.31%
Cap:
|
Volume (24h):